Drug intelligence / Profile preview

AD-209-1C

Development stage: Unknown
Lead developer: Addpharma
Administration: Oral

Overview

**AD-209-1C** is an investigational oral antihypertensive drug product developed by Addpharma for essential hypertension. It was evaluated as a distinct active intervention in Addpharma's completed randomized, double-blind Phase 2 trial NCT05631990, in which it was administered once daily for 8 weeks. Public trial records do not disclose its precise active-ingredient composition, formulation, or molecular mechanism; it should not be conflated with the related but distinct Addpharma product AD-209.

Targets

LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on AD-209-1C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-209-1C.

Explore the full profile